The rising prevalence of fibrotic diseases, such as idiopathic pulmonary fibrosis, hepatic cirrhosis, and renal fibrosis, is a significant driver of the fibrotic diseases treatment Market. Factors such as aging populations, lifestyle changes, and increasing rates of chronic conditions like diabetes and hypertension are contributing to a higher incidence of these diseases. As the number of affected individuals grows, the demand for effective treatments intensifies, driving the need for advanced therapies, including antifibrotic drugs and biologics. Healthcare systems face growing pressure to manage chronic fibrotic conditions, driving demand for more effective treatments and fueling market growth.
